logo

Magenta Therapeutics, Inc. (MGTA)



Trade MGTA now with
  Date
  Headline
6/24/2019 4:21:11 PM Magenta Therapeutics Appoints Anne McGeorge To Board Of Directors
5/10/2019 7:50:46 AM Wedbush Is Increasing Magenta Therapeutics, Inc. (MGTA) FY19 Estimate To -1.97 From -2.49
5/10/2019 7:50:32 AM Wedbush Is Raising Magenta Therapeutics, Inc. (MGTA) Q4 19 Estimate To -0.53 From -0.67
5/10/2019 7:50:09 AM Wedbush Is Raising Magenta Therapeutics, Inc. (MGTA) Q3 19 Estimate To -0.48 From -0.60
5/10/2019 7:49:56 AM Wedbush Is Raising Magenta Therapeutics, Inc. (MGTA) Q2 19 Estimate To -0.51 From -0.63
5/10/2019 7:49:24 AM Wedbush Reiterates Magenta Therapeutics, Inc. (MGTA) At Outperform With $22 Price Target
5/9/2019 7:37:58 AM Magenta Therapeutics Presents Updated Phase 2 Clinical Data On MGTA-456 Cell Therapy At AAN Annual Meeting
5/1/2019 9:43:17 PM Magenta Therapeutics Prices Public Offering Of 4.25 Mln Shares At $13.25/shr
4/24/2019 8:34:09 AM Magenta Therapeutics Announces First Subjects Dosed In Phase 1 Clinical Trial Of MGTA-145
3/19/2019 7:34:48 AM Magenta Therapeutics Q4 Net Loss $16.7 Mln Vs Net Loss $8.0 Mln Last Year
12/2/2018 9:02:21 PM Magenta Presents Data From Phase 2 Study Of MGTA-456 Cell Therapy In Patients With Inherited Metabolic Disorders
12/2/2018 9:01:53 PM Magenta Therapeutics Presents Preclinical Data On Targeted Non-Genotoxic Conditioning Programs
12/1/2018 12:34:08 PM Magenta Therapeutics Presents New Preclinical Data On MGTA-145 Stem Cell Mobilization Product Candidate
11/19/2018 8:05:53 AM Magenta Therapeutics Appoints Jason Ryan As COO And CFO, Effective Jan. 1, 2019
11/8/2018 8:09:55 AM Magenta Therapeutics Q3 Net Loss Widens To $16 Mln From $6.9 Mln Last Year
8/10/2018 7:28:40 AM Wedbush Is Increasing Magenta Therapeutics, Inc. (MGTA) FY19 Estimate To -2.09 From -2.19
8/10/2018 7:28:23 AM Wedbush Is Raising Magenta Therapeutics, Inc. (MGTA) Q4 19 Estimate To -0.58 From -0.60
8/10/2018 7:28:09 AM Wedbush Is Raising Magenta Therapeutics, Inc. (MGTA) Q3 19 Estimate To -0.51 From -0.54